|
/s/ Timothy P. Clackson
Timothy P. Clackson, Ph.D.
President and Chief Executive Officer |
| | | |
| | You are cordially invited to attend the virtual meeting. Whether or not you expect to attend the virtual meeting, please vote as soon as possible. We encourage you to vote via the internet. For further details, see “Questions and Answers about This Proxy Material and Voting.” | | |
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 8 | | | |
| | | | 18 | | | |
| | | | 21 | | | |
| | | | 23 | | | |
| | | | 28 | | | |
| | | | 30 | | | |
| | | | 31 | | | |
| | | | 32 | | | |
| | | | 33 | | | |
| | | | 34 | | | |
| | | | 35 | | | |
| | | | 37 | | | |
| | | | 37 | | | |
| | | | 37 | | | |
Appendix A | | | | | A-1 | | |
Proposal
|
| | | | |
Board of
Directors Recommendation |
| |
Vote
Required |
| |
Broker
Discretionary Voting Allowed |
|
Proposal 1:
|
| | To elect Carl Gordon and Michael Rome as Class II directors to serve until the 2026 Annual Meeting of Stockholders or until their respective successor have been elected or appointed. | | |
FOR
|
| |
Plurality
|
| |
No
|
|
Proposal 2:
|
| | To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023. | | |
FOR
|
| |
Majority
Voted |
| |
Yes
|
|
Proposal 3:
|
| | To approve an amendment to our Charter to limit the liability of certain officers of the Company as permitted by recent amendments to the Delaware General Corporation Law. | | |
FOR
|
| |
Majority of
outstanding shares |
| |
No
|
|
Name
|
| |
Age
|
| |
Position
|
|
Executive Officers: | | | | | | | |
Timothy P. Clackson, Ph.D. | | |
57
|
| |
President, Chief Executive Officer and Director
|
|
Bradford D. Dahms | | |
35
|
| | Chief Financial Officer | |
William C. Shakespeare, Ph.D. | | |
59
|
| | President of Research and Development | |
Victor M. Rivera, Ph.D. | | |
58
|
| | Chief Scientific Officer | |
David P. Kerstein, M.D. | | |
40
|
| | Chief Medical Officer | |
Non-Employee Directors: | | | | | | | |
Iain D. Dukes, MA, D.Phil. | | |
64
|
| | Chairman and Director | |
Carl Gordon, CFA, Ph.D. | | |
58
|
| | Director | |
Donald Hayden, MBA | | |
67
|
| | Lead Independent Director | |
Michael Rome, Ph.D. | | |
38
|
| | Director | |
Steven Stein, M.D. | | |
56
|
| | Director | |
Kathy Yi, MBA | | |
51
|
| | Director | |
Name
|
| |
Audit
Committee |
| |
Compensation
Committee |
| |
Nominating and
Corporate Governance Committee |
| |
Equity Awards
Committee |
| ||||||||||||
Carl Gordon, CFA, Ph.D.
|
| | | | | | | | | | | | | | | | | | | | | | | | |
Iain D. Dukes, MA, D.Phil.
|
| | | | | | | | | | | | | | | | | | | | | | | | |
Kathy Yi, MBA
|
| | | | X* | | | | | | X | | | | | | X | | | | | | | | |
Michael Rome, Ph.D.
|
| | | | X | | | | | | | | | | | | | | | | | | | | |
Timothy P. Clackson, Ph.D.
|
| | | | | | | | | | | | | | | | | | | | | | X | | |
Donald Hayden, MBA
|
| | | | X | | | | | | X* | | | | | | X* | | | | | | | | |
Steven Stein, M.D.
|
| | | | | | | | | | X | | | | | | X | | | | | | | | |
|
Total Number of Directors
|
| | | | 7 | | |
| | |
Female
|
| |
Male
|
| |
Non-Binary
|
| |
Did Not
Disclose Gender |
| ||||||||||||
Part I: Gender Identity | | | | | | | | | | | | | | | | | | | | | | | | | |
Directors
|
| | | | 1 | | | | | | 6 | | | | | | — | | | | | | — | | |
Part II: Demographic Background | | | | | | | | | | | | | | | | | | | | | | | | | |
African American or Black
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Alaskan Native or Native American
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Asian
|
| | | | 1 | | | | | | — | | | | | | — | | | | | | — | | |
Hispanic or Latino
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Native Hawaiian or Pacific Islander
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
White
|
| | | | — | | | | | | 6 | | | | | | — | | | | | | — | | |
Two or More Races or Ethnicities
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
LGBTQ+
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Did Not Disclose Demographic Background
|
| |
—
|
|
| | |
Shares Beneficially
Owned |
| |||||||||
Name of Beneficial Owner
|
| |
Number
|
| |
Percentage
|
| ||||||
Named Executive Officers and Directors: | | | | | | | | | | | | | |
Timothy P. Clackson, Ph.D.(1)
|
| | | | 1,087,567 | | | | | | 2.5% | | |
David P. Kerstein, M.D.(2)
|
| | | | 387,828 | | | | | | *% | | |
William C. Shakespeare, Ph.D.(3)
|
| | | | 939,412 | | | | | | 2.1% | | |
Iain D. Dukes, MA, D.Phil.(4)
|
| | | | 845,856 | | | | | | 1.9% | | |
Carl Gordon, CFA, Ph.D.(5)
|
| | | | 17,276,266 | | | | | | 39.6% | | |
Donald Hayden, MBA(6)
|
| | | | 30,000 | | | | | | *% | | |
Michael Rome, Ph.D.
|
| | | | — | | | | | | — | | |
Steven Stein, M.D.(7)
|
| | | | 11,666 | | | | | | *% | | |
Kathy Yi, MBA(8)
|
| | | | 109,020 | | | | | | *% | | |
All executive officers and directors as a group (11 persons)(9)
|
| | | | 21,759,849 | | | | | | 46.7% | | |
5% Stockholders: | | | | | | | | | | | | | |
Entities affiliated with OrbiMed Advisors LLC(10)
|
| | | | 17,233,668 | | | | | | 39.5% | | |
Entities affiliated with Foresite Capital(11)
|
| | | | 4,794,621 | | | | | | 11.0% | | |
Entities affiliated with FMR LLC(12)
|
| | | | 2,498,355 | | | | | | 5.7% | | |
Entities affiliated with Frazier Life Sciences Management, L.P.(13)
|
| | | | 2,248,194 | | | | | | 5.2% | | |
Purchaser
|
| |
Shares of Series B
Preferred Stock |
| |
Total Purchase
Price |
| ||||||
Entities affiliated with Foresite Capital(1)
|
| | | | 3,056,552 | | | | | $ | 34,999,997 | | |
Entities affiliated with OrbiMed Advisors LLC(2)
|
| | | | 1,309,950 | | | | | | 15,000,000 | | |
Total | | | | | 4,366,502 | | | | | $ | 49,999,997 | | |
Name and Principal Position
|
| |
Year
|
| |
Salary ($)
|
| |
Option
Awards(1) ($) |
| |
Non-Equity
Incentive Plan Compensation(2) ($) |
| |
All Other
Compensation ($) |
| |
Total ($)
|
| ||||||||||||||||||
Timothy P. Clackson, Ph.D.(3)
President, Chief Executive Officer and Director |
| | | | 2022 | | | | | | 570,000 | | | | | | 3,451,050 | | | | | | 313,500 | | | | | | 16,790(4) | | | | | | 4,351,340 | | |
| | | 2021 | | | | | | 372,239 | | | | | | 6,401,180 | | | | | | 195,640 | | | | | | ― | | | | | | 6,969,059 | | | ||
William C. Shakespeare, Ph.D.
Co-Founder, President of Research and Development |
| | | | 2022 | | | | | | 465,000 | | | | | | 1,380,420 | | | | | | 186,000 | | | | | | 15,685(5) | | | | | | 2,047,105 | | |
| | | 2021 | | | | | | 452,038 | | | | | | 1,112,055 | | | | | | 188,555 | | | | | | ― | | | | | | 1,752,648 | | | ||
David P. Kerstein, M.D.
Chief Medical Officer |
| | | | 2022 | | | | | | 465,000 | | | | | | 1,150,350 | | | | | | 186,000 | | | | | | 16,790(4) | | | | | | 1,818,140 | | |
| | | 2021 | | | | | | 409,667 | | | | | | 486,084 | | | | | | 163,330 | | | | | | ― | | | | | | 1,059,081 | | |
| | |
Option Awards
|
| |
Stock Awards
|
| ||||||||||||||||||||||||||||||||||||||||||
Name
|
| |
Vesting
Commencement Date |
| |
Number of Securities
Underlying Unexercised Options |
| |
Option
Exercise Price ($) |
| |
Option
Expiration Date |
| |
Vesting
Commencement Date |
| |
Number of
Shares that Have Not Vested (#) |
| |
Market Value
of Shares that Have Not Vested ($)(1) |
| |||||||||||||||||||||||||||
|
Vested (#)
|
| |
Unvested (#)
|
| ||||||||||||||||||||||||||||||||||||||||||||
Timothy P. Clackson, Ph.D.
|
| | | | ― | | | | | | ― | | | | | | ― | | | | | | ― | | | | | | ― | | | | | | 4/15/2021(2) | | | | | | 201,793 | | | | | | 1,004,929 | | |
| | | 2/18/2022(3) | | | | | | | | | | | | 450,000 | | | | | | 11.21 | | | | | | 2/17/2032 | | | | | | | | | | | | | | | | | | | | | ||
| | | 4/15/2021(3) | | | | | | 432,413 | | | | | | 605,380 | | | | | | 4.03 | | | | | | 4/22/2031 | | | | | | ― | | | | | | ― | | | | | | ― | | | ||
| | | 5/27/2021(4) | | | | | | 43,854 | | | | | | 66,936 | | | | | | 4.03 | | | | | | 5/26/2031 | | | | | | ― | | | | | | ― | | | | | | ― | | | ||
William C. Shakespeare, Ph.D.
|
| | | | ― | | | | | | ― | | | | | | ― | | | | | | ― | | | | | | ― | | | | | | 05/30/2018(5) | | | | | | 32,360 | | | | | | 161,154 | | |
| | | 2/18/2022(3) | | | | | | ― | | | | | | 180,000 | | | | | | 11.21 | | | | | | 2/17/2032 | | | | | | ― | | | | | | ― | | | | | | ― | | | ||
| | | 5/27/2021(4) | | | | | | 33,192 | | | | | | 194,415 | | | | | | 4.03 | | | | | | 5/26/2031 | | | | | | ― | | | | | | ― | | | | | | ― | | | ||
| | | 11/18/2020(4) | | | | | | 9,767 | | | | | | 26,299 | | | | | | 4.03 | | | | | | 3/22/2031 | | | | | | ― | | | | | | ― | | | | | | ― | | | ||
| | | 11/18/2020(4) | | | | | | 93,259 | | | | | | 251,085 | | | | | | 0.32 | | | | | | 12/23/2030 | | | | | | ― | | | | | | ― | | | | | | ― | | | ||
David P. Kerstein, M.D.
|
| | | | 2/18/2022(3) | | | | | | ― | | | | | | 150,000 | | | | | | 11.21 | | | | | | 2/17/2032 | | | | | | ― | | | | | | ― | | | | | | ― | | |
| | | 8/27/2021(3) | | | | | | 16,113 | | | | | | 32,229 | | | | | | 9.99 | | | | | | 8/26/2031 | | | | | | ― | | | | | | ― | | | | | | ― | | | ||
| | | 5/27/2021(3) | | | | | | 9,745 | | | | | | 14,875 | | | | | | 4.03 | | | | | | 5/26/2031 | | | | | | ― | | | | | | ― | | | | | | ― | | | ||
| | | 10/26/2020(3) | | | | | | 7,813 | | | | | | 6,613 | | | | | | 4.03 | | | | | | 3/22/2031 | | | | | | ― | | | | | | ― | | | | | | ― | | | ||
| | | 10/26/2020(3) | | | | | | 158,745 | | | | | | 134,323 | | | | | | 0.32 | | | | | | 12/23/2030 | | | | | | ― | | | | | | ― | | | | | | ― | | |
Name
|
| |
Fees Earned
or Paid in Cash(1) ($) |
| |
Option
Awards(2)(3) ($) |
| |
Non-Equity
Incentive Plan Compensation ($) |
| |
Total ($)
|
| ||||||||||||
Carl Gordon, Ph.D., CFA
|
| | | | 40,458 | | | | | | 119,166 | | | | | | ― | | | | | | 159,624 | | |
Iain D. Dukes, MA, D.Phil.
|
| | | | 67,285 | | | | | | 180,684 | | | | | | ― | | | | | | 247,969 | | |
Donald Hayden, MBA
|
| | | | 32,272 | | | | | | 333,306 | | | | | | ― | | | | | | 365,578 | | |
Michael Rome, Ph.D.(4)
|
| | | | ― | | | | | | ― | | | | | | ― | | | | | | ― | | |
Steven Stein, M.D.(5)
|
| | | | 9,108 | | | | | | 270,372 | | | | | | ― | | | | | | 279,480 | | |
Kathy Yi, MBA
|
| | | | 60,833 | | | | | | 119,166 | | | | | | ― | | | | | | 179,999 | | |
Position
|
| |
Annual Retainer
|
| |||
Board Member
|
| | | $ | 35,000 | | |
plus (as applicable): | | | | | | | |
Board Chair
|
| | | $ | 30,000 | | |
Lead Independent Director
|
| | | $ | 15,000 | | |
Audit Committee Chair
|
| | | $ | 15,000 | | |
Compensation Committee Chair
|
| | | $ | 10,000 | | |
Nominating and Corporate Governance Committee Chair
|
| | | $ | 8,000 | | |
Audit Committee Member
|
| | | $ | 7,500 | | |
Compensation Committee Member
|
| | | $ | 5,000 | | |
Nominating and Corporate Governance Committee Member
|
| | | $ | 4,000 | | |
Plan Category
|
| |
Number of Securities
to Be Issued Upon Exercise of Outstanding Options, Warrants and Rights |
| |
Weighted-Average
Exercise Price of Outstanding Options, Warrants and Rights |
| |
Number of Securities
Remaining Available for Future Issuance Under Equity Compensation Plans |
| |||||||||
Equity compensation plans approved by stockholders
|
| | | | 7,289,436(1) | | | | | $ | 5.95 | | | | | | 2,211,698(2) | | |
Equity compensation plans not approved by stockholders
|
| | | | — | | | | | | — | | | | | | — | | |
Total
|
| | | | 7,289,436 | | | | | $ | 5.95 | | | | | | 2,211,698 | | |
| | |
Fiscal Year Ended December 31,
|
| |||||||||
| | |
2022
|
| |
2021
|
| ||||||
Audit Fees(1)
|
| | | $ | 610,000 | | | | | $ | 1,614,500 | | |
Audit Related Fees(2)
|
| | | | — | | | | | | — | | |
Tax Fees(3)
|
| | | | — | | | | | | — | | |
All Other Fees(4)
|
| | | | — | | | | | | — | | |
Total Fees
|
| | | $ | 610,000 | | | | | $ | 1,614,500 | | |
Name
|
| |
Age
|
| |
Position
|
|
Carl Gordon, CFA, Ph.D. | | |
58
|
| |
Director
|
|
Michael Rome, Ph.D. | | |
38
|
| |
Director
|
|
| | | | THESEUS PHARMACEUTICALS, INC. | |
| | | |
By:
Name: Timothy P. Clackson, Ph.D.
Title: President and Chief Executive Officer |
|